Two novel agents targeting angiopoietin-like protein 3 demonstrated safety and lipid-lowering capabilities in phase 2 trials, ...

A Phase III trial of the antisense agent mipomersen in patients with ... in levels of low-density lipoprotein (LDL)–cholesterol after 26 weeks of treatment. Mipomersen — which is being ...

Results of the ARBITER 6–HALTS trial indicate a superiority of the lipid-modifying agent nicotinic acid over ezetimibe for the treatment of atherosclerotic lesions. These findings could have ...